Corporate Support
Sitemap
Singapore

ShareInvestor.com

Mobile Edition
Mode - Streaming
Switch to Static Mode?

Price Highlight

Index Highlight

Chart
STI
3,294.9
0.0 (0.00%)

 

  • STI Straits Times Index
    3,294.9
    0.0 (0.00%)
     
  • KLCI FTSE Bursa Malaysia KLCI
    1,527.1
    -0.7 (-0.05%)
    Index delayed 15 minutes
  • HSI Hang Seng Index
    24,965.5
    13.2 (0.05%)
    Index delayed 15 minutes
  • SSE SSE Composite Index
    3,522.6
    -32.5 (-0.91%)
    Index delayed 15 minutes

SGX Market

Bursa Market

HKEx Market

SET Market

IDX Market

ASX Market

NYSE Market

NASDAQ Market

NYSE American Market

  • Volume: 805.0M
  • Value: 1,097.8M
  • Rise: 135
  • Fall: 158
  • Unch: 474

Intraday Market Ticker Help

Intraday Market Ticker
Time Name Type Price Vol
  • Top Active

  • Top Gainer

  • Top Loser

Top Counters
Name Last Change
Jiutian Chemical0.086+0.003
DISA0.009+0.001
ThaiBev0.660+0.005
The Place Hldg0.074+0.016
Geo Energy Res0.355+0.025
Sembcorp Marine0.083-
Arion Ent0.011+0.001
Singtel2.480+0.010
Oceanus0.029+0.001
Genting Sing0.775-0.005

World Indices

World Indices
Name Last Change
Nasdaq 13,768.9 -385.1
HSI 24,965.5 +13.2
HSCEI 8,787.3 +25.7
Jakarta 6,726.4 +99.5
Nikkei 225 27,522.3 -250.7
SSE Comp 3,522.6 -32.5
Shanghai A 3,691.5 -34.1
Shanghai B 286.2 -0.8
KOSPI 2,834.3 -28.4

Nikkei 225 updated at end-of-day. Other Asian Indices delayed. US Indices updated twice daily at 7:30am and 7:30pm.

Fundamental - Factsheet

Help
  • Factsheet

  • Print

PFIZER INC PFIZER
Updated on 21 Jan 2022 (End of trading day)
Last (USD): 52.790 Change: -1.260 High: 54.865 Remarks: -
Change (%): -2.33 Low: 52.464
Open 54.420 Yesterday's Close 54.05
Buy Price - Sell Price -
Buy Volume (share) - Sell Volume (share) -
Cumulative Volume (share) 40,973,970 Cumulative Value

Company Background

Pfizer Inc. is a research-based global biopharmaceutical company. It engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Click to show Stock Prices chart

Key Statistics

EPS (USD) a 1.71321 Trailing EPS (USD) b 3.41715 NAV (USD) c 13.4851
PE a 30.814 Trailing PE d 15.449 Price / NAV c 3.9147
Dividend Yield (%) e 2.875 Cash In Hand (USD) f 0.3503 Issued & Paid-up Shares g 5,612,870,000
Piotroski F Score 4 Market Cap (M) 296,303.407 Free Float (%) -
Return on Equity (ROE) (%) h 25.340 Revenue Growth (%) TTM i n.a.
Net Earnings Growth (%) j n.a. Net Debt/Equity k 0.135
Sector & Industry Health Technology - Pharmaceuticals: Major
Notes:
  1. Based on latest Full Year results announcement, adjusted based on Profit Attributable To Shareholders.
  2. Summation of the earnings from the latest 4 Quarter (or 2 Half Year) results announcement, adjusted for the current number of shares.
  3. Based on latest results announcement (Full Year, Half Year or Interim), adjusted for carrying value of "Other Share Capital", illustrative financial effects of corporate actions (if applicable) and the current number of shares.
  4. Based on latest Full Year results announcement, adjusted for the current number of shares.
  5. Dividend is based on latest Full Year results announcement, adjusted for current number of shares and excludes special dividend.
  6. Based on reported cash and cash equivalents at end and extracted from the latest results announcement (Full Year, Half Year or Interim), adjusted for the current number of shares.
  7. Rounded to the nearest thousand. The figure pertains to the respective exchange the stock is listed on. Updated on 22 Nov 2021. Please click here for more information.
  8. Calculated based on Net Earnings / (Shareholders' Equity - Other Share Capital)
  9. Calculated based on (Current Year Revenue - Last Year Revenue) / Last Year Revenue
  10. Calculated based on (Current Year Earnings - Last Year Earnings) / Last Year Earnings
  11. Calculated based on (Long Term Debt + Short Term Debt - Cash and Short Term Investments)/(Shareholders' Equity - Other Share Capital)

Total Shareholder Return

PeriodDividend ReceivedCapital AppreciationTotal Shareholder Return
Short Term Return 5 Days --2.160
-3.93 %
10 Days --2.930
-5.26 %
20 Days --5.920
-10.08 %
Medium Term Return 3 Months 0.390+9.630
+23.22 %
6 Months 0.780+11.110
+28.53 %
1 Year 1.560+16.240
+48.70 %
Long Term Return 2 Years 3.080+12.970
+40.31 %
3 Years 4.520+12.150
+41.02 %
5 Years 7.160+21.370
+90.80 %
Annualised Return Annualised --
+13.79 %
Notes:
  1. Total Shareholder Return (TSR) combines share price appreciation and dividends paid to show the total return to the shareholder expressed as a percentage.
  2. Script dividends are ignored in this calculation.

Peer Comparison

Type Name Market Market Cap (M)a PE b Trailing PE c Price / NAV d Dividend Yield (%)d
Reference PFIZER INC NYSE 296,303.407 30.814 15.449 3.9147 2.875
Industry Pharmaceuticals: Major NYSE 116,733.444 35.280 26.297 5.5883 1.940
Local Peer JOHNSON & JOHNSON NYSE 434,036.762 29.498 24.275 6.1765 2.414
Local Peer ABBVIE INC NYSE 233,324.802 51.213 31.294 17.2196 3.662
Local Peer ELI LILLY AND COMPANY NYSE 232,509.252 37.540 38.931 29.9741 1.218
Local Peer NOVARTIS AG ADR-EACH REPR 1 CHF0.5(REGD) NYSE 211,867.573 26.247 21.604 3.7320 -
Local Peer MERCK & CO INC NYSE 202,024.681 28.587 28.071 5.6441 3.106
Local Peer NOVO NORDISK A/S ADR-EACH CNV INTO 1 CLASS B DKK1 NYSE 169,031.322 26.231 22.771 16.4043 -
Local Peer BRISTOL-MYERS SQUIBB CO NYSE 141,036.561 - - 3.7900 2.928
Local Peer GLAXOSMITHKLINE ADR EACH CNV INTO 2 ORD GBP0.25 NYSE 113,467.090 15.391 19.122 5.4552 -
Local Peer TAKEDA PHARMACEUTICAL CO LTD SPON ADS EACH REP 0.5 ORD SHS NYSE 46,391.717 13.085 10.501 0.9722 -
Local Peer ORGANON & CO NYSE 7,852.444 3.635 5.176 -4.8532 -
Local Peer BIOHAVEN PHARMACEUTICAL HLDG CO LTD NYSE 7,592.229 - - -12.9125 -
Local Peer EMERGENT BIOSOLUTIONS INC NYSE 2,526.925 8.282 11.132 1.6595 -
Other Local Peers AMNEAL PHARMACEUTICALS INC (NYSE), ADC THERAPEUTICS SA (NYSE), ZYMEWORKS INC (NYSE), ANNOVIS BIO INC (NYSE), LANNETT CO INC (NYSE)
Global Peer ASTRAZENECA SPON ADR EACH REP 0.50 ORD SHS NASDAQ 183,139.080 57.302 124.500 4.6080 -
Global Peer SANOFI SPON ADR ECH REP 0.5 ORD SHS NASDAQ 129,489.629 9.224 18.699 1.7267 -
Global Peer WUXI APPTEC CO LTD HKEx 359,491.010 108.314 72.361 7.9831 0.289
Global Peer ROYALTY PHARMA PLC NASDAQ 23,764.790 24.373 30.358 4.1023 0.490
Global Peer VIATRIS INC NASDAQ 17,572.437 - - 0.8312 -
Global Peer HANSOH PHARMACEUTICAL GROUP CO LTD HKEx 110,866.392 38.406 35.879 4.9280 0.412
Global Peer REPLIGEN CORP NASDAQ 10,162.579 169.585 85.487 5.9248 -
Global Peer INNOVENT BIOLOGICS INC HKEx 61,116.198 - - 4.2713 -
Global Peer SINOPHARM GROUP CO. LTD. HKEx 58,106.689 7.195 6.309 0.8366 4.508
Global Peer EVOTEC SE SPON ADS EACH REP 0.50 ORD SHS NASDAQ 6,998.939 981.791 23.759 6.0836 -
Other Global Peers CANSINO BIOLOGICS INC (HKEx), ASCENDIS PHARMA A/S SPON ADR EACH REP 1 ORD SHS (NASDAQ), SHANGHAI JUNSHI BIOSCIENCES CO LTD (HKEx), LEGEND BIOTECH CORP SPON ADS EACH REP 2 ORD SHS (NASDAQ), SHANGHAI PHARMACEUTICALS HOLDING CO (HKEx), HUTCHMED (CHINA) LIMITED (HKEx), HUTCHMED (CHINA) LIMITED SPON ADS EACH REPR 5 ORD SHS (NASDAQ), CHINA MEDICAL SYSTEM HLDGS LTD (HKEx), GUANGZHOU BAIYUNSHAN PHARMACEUTICAL (HKEx), CUREVAC NV (NASDAQ), REMEGEN CO LTD (HKEx), CEREVEL THERAPEUTICS HLDGS INC (NASDAQ), APELLIS PHARMACEUTICALS INC (NASDAQ), HYGEIA HEALTHCARE HLDGS CO LTD (HKEx), CHINA TRADITIONAL CHINESE MED HLDGS (HKEx), KARUNA THERAPEUTICS INC (NASDAQ), GRIFOLS SA SPON ADR EA REPR 1 ORD EUR0.10 (NASDAQ), CHINA RESOURCES PHARMACEUTICAL GR (HKEx), SIMCERE PHARMACEUTICAL GRP LTD (HKEx), OPKO HEALTH INC (NASDAQ), GRAND PHARMACEUTICAL GROUP LTD (HKEx), AKESO INC (HKEx), SPRINGWORKS THERAPEUTICS INC (NASDAQ), I MAB SPON ADS EACH REP 2.3 ORD SHS (NASDAQ), INNOCARE PHARMA LTD (HKEx), IMMUNITYBIO INC (NASDAQ), EQRX INC (NASDAQ), NEKTAR THERAPEUTICS (NASDAQ), HARMONY BIOSCIENCES HLDGS INC (NASDAQ), TURNING POINT THERAPEUTICS INC (NASDAQ), CLOVER BIOPHARMACEUTICALS LTD (HKEx), SHANGHAI HENLIUS BIOTECH INC (HKEx), SHENZHEN HEPALINK PHARMACEUTICAL (HKEx), CARSGEN THERAPEUTICS HLDGS LTD (HKEx), SSY GROUP LIMITED (HKEx), ERASCA INC (NASDAQ), BEIJING TONG REN TANG CHINESE MEDIC (HKEx), OCUMENSION THERAPEUTICS (HKEx), EVEREST MEDICINES LTD (HKEx), AMYLYX PHARMACEUTICALS INC (NASDAQ), UNITED LABORATORIES INTL HLDGS LTD (HKEx), CSTONE PHARMACEUTICALS (HKEx), KEROS THERAPEUTICS INC (NASDAQ), PROCAPS GROUP S.A. (NASDAQ), QUANTERIX CORPORATION (NASDAQ), CRINETICS PHARMACEUTICALS INC (NASDAQ), REATA PHARMACEUTICALS INC (NASDAQ), DAY ONE BIOPHARMACEUTICALS INC (NASDAQ), CK LIFE SCIENCES INTL HLDG (HKEx), ZEALAND PHARMA AS SPON ADR EACH REP 1 ORD SHS (NASDAQ), ATAI LIFE SCIENCES NV (NASDAQ), GH RESEARCH PLC (NASDAQ), Kimia Farma Tbk. (IDX), NURIX THERAPEUTICS INC (NASDAQ), GOSSAMER BIO INC (NASDAQ), PHIBRO ANIMAL HEALTH CORP (NASDAQ), CENTESSA PHARMACEUTICALS PLC SPON ADS EACH REPR 1 ORD SHS (NASDAQ), ARCUTIS BIOTHERAPEUTICS INC (NASDAQ), SCICLONE PHARMACEUTICALS (HLDGS) LT (HKEx), KINIKSA PHARMACEUTICALS LTD (NASDAQ), ABBISKO CAYMAN LTD (HKEx), AKERO THERAPEUTICS INC (NASDAQ), CHINOOK THERAPEUTICS INC (NASDAQ), ARCTURUS THERAPEUTICS HOLDINGS INC (NASDAQ), AMRYT PHARMA PLC (NEW) SPON ADS EACH REP 5 ORD SHS (NASDAQ), ANTENGENE CORP LTD (HKEx), ICOSAVAX INC (NASDAQ), PRAXIS PRECISION MEDICINES INC (NASDAQ), IGM BIOSCIENCES INC (NASDAQ), CHINA SHINEWAY PHARMACEUTICAL GR (HKEx), PHARVARIS NV (NASDAQ), PETIQ INC (NASDAQ), IDEAYA BIOSCIENCES INC (NASDAQ), Soho Global Health Tbk. (IDX), CALLIDITAS THERAPEUTICS AB SPON ADS EACH REP 2 ORD SHS (NASDAQ), ATEA PHARMACEUTICALS INC (NASDAQ), IMMUNOTECH BIOPHARM LTD (HKEx), REPARE THERAPEUTICS INC (NASDAQ), CINCOR PHARMA INC (NASDAQ), KINNATE BIOPHARMA INC (NASDAQ), MIRUM PHARMACEUTICALS INC (NASDAQ), CULLINAN ONCOLOGY INC (NASDAQ), KRONOS BIO INC (NASDAQ), RELMADA THERAPEUTICS INC (NASDAQ), POINT BIOPHARMA GLOBAL INC (NASDAQ), TRANSCENTA HOLDING LTD (HKEx), FORMA THERAPEUTICS HLDGS INC (NASDAQ), FULCRUM THERAPEUTICS INC (NASDAQ), Y-MABS THERAPEUTICS INC (NASDAQ), PHATHOM PHARMACEUTICALS INC (NASDAQ), SIGA TECHNOLOGIES INC (NASDAQ), 2SEVENTY BIO INC (NASDAQ), SUTRO BIOPHARMA INC (NASDAQ), HUA MEDICINE (HKEx), TRICIDA INC (NASDAQ), ORIC PHARMACEUTICALS INC (NASDAQ), ALPHA TEKNOVA INC (NASDAQ), OCULAR THERAPEUTIX INC (NASDAQ), MIND MEDICINE (MINDMED) INC (NASDAQ), IGBB (Bursa), VERU INC (NASDAQ), XILIO THERAPEUTICS INC (NASDAQ), CANBRIDGE PHARMACEUTICALS INC (HKEx), ALLAKOS INC (NASDAQ), SPERO THERAPEUTICS INC (NASDAQ), TENAYA THERAPEUTICS INC (NASDAQ), TALARIS THERAPEUTICS INC (NASDAQ), G1 THERAPEUTICS IN (NASDAQ), REGENCELL BIOSCIENCE HLDGS LTD (NASDAQ), TARSUS PHARMACEUTICALS INC (NASDAQ), ZHAOKE OPHTHALMOLOGY LTD (HKEx), GENERATION BIO CO (NASDAQ), RACE ONCOLOGY LTD (ASX), ESSA PHARMA INC (NASDAQ), GRITSTONE BIO INC (NASDAQ), OYSTER POINT PHARMA INC (NASDAQ), STARPHARMA HOLDINGS LIMITED (ASX), ADAGENE INC SPON ADS EACH REP 1.25 ORD SHS (NASDAQ), VACCITECH PLC ADR EACH REPR 1 ORD SH SPON (NASDAQ), AC IMMUNE SA (NASDAQ), LANDEC CORP (NASDAQ), FUSION PHARMACEUTICALS INC (NASDAQ), TOT BIOPHARM INTL CO LTD (HKEx), NANOBIOTIX S A SPON ADS EACH REP 1 ORD SHS (NASDAQ), PYXIS ONCOLOGY INC (NASDAQ), EVOLUS INC (NASDAQ), EYEPOINT PHARMACEUTICALS INC (NASDAQ), AFT PHARMACEUTICALS LTD (ASX), ANNEXON INC (NASDAQ), PYC THERAPEUTICS LIMITED (ASX), LIQUIDIA CORPORATION (NASDAQ), DAWNRAYS PHARMACEUTICAL HLDGS (HKEx), KALVISTA PHARMACEUTICALS INC (NASDAQ), CONNECT BIOPHARMA HLDGS LTD ADS EACH REP ONE ORD SHARE (NASDAQ), THERATECHNOLOGIES INC (NASDAQ), IMMUNIC INC (NASDAQ), PROVENTION BIO INC (NASDAQ), EVELO BIOSCIENCES INC (NASDAQ), COMPASS THERAPEUTICS INC (NASDAQ), BSTEAD (Bursa), OLEMA PHARMACEUTICALS INC (NASDAQ), XOMA CORP (NASDAQ), CITIUS PHARMACEUTICALS INC (NASDAQ), HARROW HEALTH INC (NASDAQ), PHARMA (Bursa), VERRICA PHARMACEUTICALS INC (NASDAQ), 89BIO INC (NASDAQ), BIOMEA FUSION INC (NASDAQ), OVID THERAPEUTICS INC (NASDAQ), MILESTONE PHARMACEUTICALS INC (NASDAQ), NRX PHARMACEUTICALS INC (NASDAQ), WEREWOLF THERAPEUTICS INC (NASDAQ), ACUMEN PHARMACEUTICALS INC (NASDAQ), IMPEL NEUROPHARMA INC (NASDAQ), RENEO PHARMACEUTICALS INC (NASDAQ), CHECKPOINT THERAPEUTICS INC (NASDAQ), IP (SET), GENENTA SCIENCE SPA SPON ADS EACH REP 1 ORD SHS (NASDAQ), VECTIVBIO HLDG AG (NASDAQ), TFF PHARMACEUTICALS INC (NASDAQ), GAMIDA CELL LTD (NASDAQ), PDS BIOTECHNOLOGY CORPORATION (NASDAQ), RECCE PHARMACEUTICALS LTD (ASX), CLENE INC (NASDAQ), CYBIN INC (NYSE American), NAVIDEA BIOPHARMACEUTICALS INC (NYSE American), SOL GEL TECHNOLOGIES LTD (NASDAQ), ANEBULO PHARMACEUTICALS INC (NASDAQ), ACHILLES THERAPEUTICS PLC ADS EACH REPR 1 SHARE SPON (NASDAQ), INOZYME PHARMA INC (NASDAQ), DURECT CORP (NASDAQ), CODIAK BIOSCIENCES INC (NASDAQ), OBSEVA SA (NASDAQ), REDHILL BIOPHARMA LTD SPON ADS EA REPR 10 ORD ILS0.00 (NASDAQ), SILVERBACK THERAPEUTICS INC (NASDAQ), ALZAMEND NEURO INC (NASDAQ), CHINA BIOTECH SERVICES HLDGS LTD (HKEx), SATSUMA PHARMACEUTICALS INC (NASDAQ), VINCERX PHARMA INC (NASDAQ), BROOKLYN IMMUNO THERAPEUTICS INC (NASDAQ), BOLT BIOTHERAPEUTICS INC (NASDAQ), BEYONDSPRING INC (NASDAQ), TCR2 THERAPEUTICS INC (NASDAQ), ORCHARD THERAPEUTICS PLC SPON ADS EACH REPR 1 ORD SHS (NASDAQ), AQUESTIVE THERAPEUTICS INC (NASDAQ), ALIGOS THERAPEUTICS INC (NASDAQ), MUSTANG BIO INC (NASDAQ), Merck Tbk. (IDX), DARE BIOSCIENCE INC (NASDAQ), KOTRA (Bursa), FUSEN PHARMACEUTICAL CO LTD (HKEx), CLEARSIDE BIOMEDICAL INC (NASDAQ), ATHENEX INC (NASDAQ), SCPHARMACEUTICALS INC (NASDAQ), IX Biopharma (SGX), ZHONGZHI PHARMACEUTICAL HLDGS LTD (HKEx), MINK THERAPEUTICS INC (NASDAQ), PROPHASE LABS INC (NASDAQ), PHASEBIO PHARMACEUTICALS INC (NASDAQ), 4D PHARMA PLC SPONS ADR EACH REP 8 ORD SHS (NASDAQ), JP (SET), ASSERTIO HOLDINGS INC (NASDAQ), INVION LTD (ASX), GENPREX INC (NASDAQ), ONCTERNAL THERAPEUTICS INC (NASDAQ), KALEIDO BIOSCIENCES INC (NASDAQ), TYME TECHNOLOGIES INC (NASDAQ), AYALA PHARMACEUTICALS INC (NASDAQ), EYENOVIA INC (NASDAQ), ETON PHARMACEUTICALS INC (NASDAQ), POLYPID LTD (NASDAQ), NEW RAY MEDICINE INTL HLDG LTD (HKEx), RVL PHARMACEUTICALS PLC (NASDAQ), ADAMIS PHARMACEUTICALS CORPORATION (NASDAQ), APPLIED THERAPEUTICS INC (NASDAQ), NOXOPHARM LTD (ASX), 180 LIFE SCIENCES CORP (NASDAQ), CORVUS PHARMACEUTICALS INC (NASDAQ), QILIAN INTERNATIONAL HLDG GROUP LTD (NASDAQ), ABVC BIOPHARMA INC (NASDAQ), JOURNEY MEDICAL CORPORATION (NASDAQ), F-STAR THERAPEUTICS INC (NASDAQ), CRESO PHARMA LTD (ASX), CHARMACY PHARMACEUTICAL CO LTD (HKEx), VTV THERAPEUTICS INC (NASDAQ), NOVA (Bursa), ORPHAZYME A/S SPON ADS REP 1 ORD SHS (NASDAQ), GALERA THERAPEUTICS INC (NASDAQ), NEXIMMUNE INC (NASDAQ), MANNATECH INC (NASDAQ), AKARI THERAPEUTICS PLC SPON ADR EACH REPR 100 ORD (NASDAQ), LANTERN PHARMA INC (NASDAQ), ENTERA BIO LTD (NASDAQ), Hyphens Pharma (SGX), Phapros Tbk. (IDX), MEDIWOUND LTD (NASDAQ), ALLARITY THERAPEUTICS INC (NASDAQ), ANGION BIOMEDICA CORP (NASDAQ), PROTARA THERAPEUTICS INC (NASDAQ), MODERN CHINESE MEDICINE GRP CO LTD (HKEx), NEW CENTURY HEALTHCARE HLDGS CO LTD (HKEx), NOVAN INC (NASDAQ), PAK FAH YEOW INTERNATIONAL (HKEx), PURPLE BIOTECH LTD SPON ADS EACH REP 10 ORD SHS (NASDAQ), OCUPHIRE PHARMA INC (NASDAQ), EDESA BIOTECH INC (NASDAQ), BIOFRONTERA INC (NASDAQ), APTORUM GROUP LIMITED (NASDAQ), GALECTO INC (NASDAQ), LOGICBIO THERAPEUTICS INC (NASDAQ), ELEDON PHARMACEUTICALS INC (NASDAQ), KALA PHARMACEUTICALS INC (NASDAQ), VIRIOS THERAPEUTICS INC (NASDAQ), SYNAPTOGENIX INC (NASDAQ), NEUBASE THERAPEUTICS INC (NASDAQ), BIOHLDG (Bursa), HOOKIPA PHARMA INC (NASDAQ), CYCLERION THERAPEUTICS INC (NASDAQ), EXOPHARM LTD (ASX), ADIAL PHARMACEUTICALS INC (NASDAQ), APREA THERAPEUTICS INC (NASDAQ), LYRA THERAPEUTICS INC (NASDAQ), MOLECULIN BIOTECH INC (NASDAQ), ADDEX THERAPEUTICS LIMITED SPON ADS EACH REP 6 ORD SHS (NASDAQ), IMARA INC (NASDAQ), WAI YUEN TONG MEDICINE HOLDINGS LTD (HKEx), SUNZEN (Bursa), ACURX PHARMACEUTICALS INC (NASDAQ), PHARMAXIS (ASX), PURAPHARM CORPORATION LIMITED (HKEx), AILERON THERAPEUTICS INC (NASDAQ), IMMIX BIOPHARMA INC (NASDAQ), SANAI HEALTH INDUSTRY GP CO LTD (HKEx), SHENZHEN NEPTUNUS INTERLONG BIO-TEC (HKEx), UNIVERSE PHARMACEUTICALS INC (NASDAQ), INHIBIKASE THERAPEUTICS INC (NASDAQ), MEDLAB CLINICAL LIMITED (ASX), AYTU BIOPHARMA INC (NASDAQ), CLARUS THERAPEUTICS HLDGS INC (NASDAQ), PALLA PHARMA LTD (ASX), VYNE THERAPEUTICS INC (NASDAQ), THE HYDRATION PHARMACEUTICALS LTD (ASX), RENOVORX INC (NASDAQ), PETROS PHARMACEUTICALS INC (NASDAQ), VALLON PHARMACEUTICALS INC (NASDAQ), AGEX THERAPEUTICS INC (NYSE American), JCT (SET), ALLENA PHARMACEUTICALS INC (NASDAQ), ACER THERAPEUTICS INC (NASDAQ), VIRPAX PHARMA INC (NASDAQ), BONE BIOLOGICS CORP (NASDAQ), BRICKELL BIOTECH INC (NASDAQ), EXTRAWELL PHARMACEUTICAL HLDGS (HKEx), GRAYBUG VISION INC (NASDAQ), PASITHEA THERAPEUTICS CORP (NASDAQ), CINGULATE INC (NASDAQ), REVIVA PHARMACEUTICALS HOLDINGS INC (NASDAQ), TEMPEST THERAPEUTICS INC (NASDAQ), ONCOSIL MEDICAL LIMITED (ASX), IMMURON LIMITED (ASX), XORTX THERAPEUTICS INC (NASDAQ), PANBELA THERAPEUTICS INC (NASDAQ), BIONDVAX PHARMACEUTICALS SPON ADS REP 40 ORD SHS (NASDAQ), ACRUX (ASX), TISSUE REPAIR LTD (ASX), IMMURON LIMITED SPON ADR EACH REPR 40 ORD SHS (NASDAQ), TIMBER PHARMACEUTICALS INC (NYSE American), CNS PHARMACEUTICALS INC (NASDAQ), SEQLL INC (NASDAQ), YUMANITY THERAPEUTICS INC (NASDAQ), ARIDIS PHARMACEUTICAL INC (NASDAQ), TREVI THERAPEUTICS INC (NASDAQ), SCISPARC LTD (NASDAQ), HOTH THERAPEUTICS INC (NASDAQ), BAUDAX BIO INC (NASDAQ), BIOME AUSTRALIA LT (ASX), AVENUE THERAPEUTICS INC (NASDAQ), NANJING SINOLIFE UNITED COMPANY LTD (HKEx), ISLAND PHARMACEUTICALS LTD (ASX), DERMATA THERAPEUTICS INC (NASDAQ), PA SHUN INTERNATIONAL HOLDINGS LTD (HKEx), AROVELLA THERAPEUTICS LTD (ASX), PAINREFORM LTD (NASDAQ), TALI DIGITAL LIMITED (ASX), NLS PHARMACEUTICS LTD (NASDAQ), FIJI KAVA LTD (ASX), TITAN PHARMACEUTICAL INC (NASDAQ), FARMAFORCE LTD (ASX), CHINA SXT PHARMACEUTICALS INC (NASDAQ), Pharmesis Intl (SGX)
Notes:
  1. For companies, Market Cap is based on the trading currency of the company. Industry/Index Market Cap is the average market cap for that industry/index.
  2. Industry/Index PE is calculated using (Total Market Cap/Total Earnings) of all companies in the industry/index.
  3. Industry/Index Price/NAV is calculated using (Total Market Cap/Total Shareholders' Equity) of all companies in the industry/index.
  4. Industry/Index Dividend Yield is calculated using (Total Gross Dividend/Total Market Cap) of all companies in the industry/index.
  5. For Industry/Index calculation, data for foreign currency denominated companies will be converted to the main market currency using the latest exchange rate.
  6. Industry/Index/Peers data is updated daily.
  7. Peers are sorted by market capitalisation and only details for the top 10 will be shown.

More Information Available

More information is available to our subscribers, including:

  • Consensus Estimates
  • Comprehensive Financial Ratios(ROA, ROE, Price/Revenue, Net Earnings Margin, Current Ratio, Debt to Equity Ratio etc)
  • Insider Buying and Selling Report

If you are an existing subscriber, please login. If not, read up on what you are missing out in our Help Centre and join us as a subscriber.

Disclaimer:

While reasonable efforts have been taken to ensure that the calculations performed by the features of this site are reliable, the features are provided on the basis that:-

  1. no liability is accepted for any errors or inaccuracies resulting from your use of these features;
  2. many of the data inputs (including share prices) are obtained from third party sources for which we assume no responsibility.
We use Cookies. By continuing to use this webite, you will be agreeing to our Privacy Policy, Terms and Conditions and Cookie Policy.